skip to Main Content

New Zolgensma Clinical Trial

  • 21 April 2021

A new clinical trial is starting for gene therapy for patients who are: Symptomatic SMA diagnosis based on gene mutation analysis with bi-allelic survival motor neuron 1 (SMN1) mutations (deletion or point mutations) and any copy of the survival motor…

Read More

Zolgensma NHSE Announcement

  • 8 March 2021

An agreement between NHSE and Novartis Gene Therapies has been reached to enables families in England to have access to gene therapy for Spinal Muscular Atrophy.

Read More
Back To Top